The Secretary of the 19th Expert Committee on the Selection and Use of Essential Medicines Medicine Access and Rational Use (MAR) Department of Essential Medicine and Health Products World Health Organization 20 Avenue Appia CH-1211 Geneva 27 SWITZERLAND E-mail:
[email protected] January 28, 2013 A Joint Support Letter Signed by ITPC-China and Its Member NGOs for the MSF Application for Inclusion of Pegylated Interferon on the WHO EML Dear Sir or Madam: ITPC-China is a national activist and NGO coalition on advocacy for people with HIV, TB and viral hepatitis. The Coalition hereby supports the application for the inclusion of pegylated interferon (PEG-IFN) alfa 2a 2b on the WHO Model List of Essential Medicines (EML). In China, there are approximately 10 million people living with HCV. However, according to the Annual National Infectious Disease Reporting Incidence and Mortality Statistics published by the Chinese Ministry of Health, newly reported cases of HCV have shown a double digital growth between 2007 and 2011. Very few Chinese receive treatment for HCV, as the cost is prohibitively high. While the overall HCV infection rate in China is relatively low, the total number of people needing treatment is still high, and the rate of co-infection among people living with HIV (PLHIV) is alarming. Among an estimated 780,000 PLHIV in China1, injecting drug users (IDU) account for 28.4% and former plasma donors and former contaminated blood or blood product recipients account for 6.6%.A recent survey of HIV-1 positive injection drug uses (IDU), former paid blood donors (FBD)2 and sexually transmitted cases from multiple provinces including the four most affected provinces in China found that IDU and FBD have extremely high rates of HCV infection (97% and 93%, respectively).